Accessibility Menu
Arcutis Biotherapeutics logo

Arcutis Biotherapeutics(NASDAQ) ARQT

Market Cap$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+16%
5 Year+18%
1 Year+79%
1 Month-11%
$25.63
+1.34%
+0.34Today
Arcutis Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 25.292026-08-07
Arcutis Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.85%USD 26.862026-07-31
1 month-11.26%USD 28.502026-07-08
3 month+19.46%USD 21.172026-05-08
Year to date-12.91%USD 29.042025-12-31
1 year+79.11%USD 14.122025-08-07
3 year+157.27%USD 9.832023-08-08
5 year+17.9%USD 21.452021-08-06
Since inception+16.01%USD 21.802020-01-31

Arcutis Biotherapeutics Financials at a Glance

Market Cap

$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$463.98M

Net Income (TTM)

$28.52M

EPS (TTM)

$0.21

P/E Ratio

122.11

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$25.63

Volume

1,165,561.689

Open

$24.93

Previous Close

$25.29

Daily Range

$24.76 - $25.95

52-Week Range

$14.03 - $31.77

Estimated Earnings Date

Oct 27, 2026

ARQT News

SellAlert-Red.png

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Sarah SidlowAug 6, 2026
TMF-Pills-Blue-StockVStock.png

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Brendan CoffeyJul 3, 2026
SellAlert-Blue.png

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%

Jonathan PoncianoJun 23, 2026
SellAlert-Blue.png

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know

Jonathan PoncianoApr 8, 2026
SellAlert-Blue.png

This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit

Jonathan PoncianoFeb 6, 2026
SellAlert-Red.png

Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares

Jonathan PoncianoDec 23, 2025
GettyImages-184697460-1201x838-c60e038

This Biotech Stock Could Cure Your Portfolio's Pain

Lee SamahaDec 14, 2025
kids mom fun with garden hose-1201x823-4f47a75

Why Shares in Arcutis Biotherapeutics Surged Again This Week

Lee SamahaNov 21, 2025
Page 1

ARQT: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arcutis Biotherapeutics

Arcutis makes skin creams and foams to treat common rashes. These medicines help people with psoriasis and itchy skin conditions. The company sells its products across the United States and Canada.

Creams and Foams for Better Skin

  • ZORYVE foam: Steroid-free treatment for seborrheic dermatitis and scalp psoriasis; accounts for 47% of revenue.
  • ZORYVE cream 0.3%: Topical formulation used to treat plaque psoriasis in adults and children; generates 31% of revenue.
  • ZORYVE cream 0.15%: Medicine for mild to moderate atopic dermatitis in patients aged six and older; makes up 21% of revenue.
  • ZORYVE cream 0.05%: Lower-concentration cream designed for children aged two to five with atopic dermatitis; contributes 1% of revenue.

Building a Global Presence

  • Purchased Ducentis Biotherapeutics LTD in 2022 to add a new biological treatment to the pipeline.
  • Entered a licensing deal with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. in 2023 for rights in China.
  • Formed a partnership with Sato Pharmaceutical Co., Ltd. in February 2024 to develop products in Japan.
  • Ended a promotion agreement with Kowa Pharmaceuticals America, Inc. in January 2026.

Focusing on Chronic Skin Care

The company avoids steroids by using phosphodiesterase-4 (PDE4) inhibitors, which block enzymes that cause skin inflammation. Its development platform focuses on validated biological targets to reduce the risk of clinical failure.

The Financial Picture

  • Revenue reached $105.4 million in Q1 2026, up 60.1% from Q1 2025.
  • Net loss narrowed to $11.3 million in Q1 2026, improving 54.9% from the previous year.
  • Free cash flow turned positive at $2.2 million in Q1 2026, up from a $31 million loss in Q1 2025.
  • Market cap reached $3 billion in Q1 2026, up 54.6% year-over-year.

Evolution in Dermatology

Arcutis has transitioned from a research-focused firm to a commercial-stage company with multiple approved products. Its focus on non-steroidal treatments allows it to compete in large markets for chronic skin diseases.

AI Generated • May 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

354

CEO

Todd Franklin Watanabe

Website

www.arcutis.com

Headquarters

Westlake Village, CA 91361, US

ARQT Financials

Key Financial Metrics (TTM)

Gross Margin

91.14%

Operating Margin

7.38%

Net Income Margin

6.15%

Return on Equity

15.05%

Return on Capital

-6.25%

Return on Assets

5.84%

Earnings Yield

0.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

125.69M

Volume

1.17M

Avg. Volume

1.80M

Financials (TTM)

Gross Profit

$422.89M

Operating Income

$34.25M

EBITDA

$44.13M

Operating Cash Flow

$41.55M

Capital Expenditure

-$158.00K

Free Cash Flow

$41.39M

Cash & ST Invst.

$238.55M

Total Debt

$114.14M

Arcutis Biotherapeutics Performance Analysis

Arcutis Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,686,000N/A
20232023-12-31USD 59,606,0001517.1%
20242024-12-31USD 196,542,000229.7%
20252025-12-31USD 376,072,00091.3%
Arcutis Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3021.7%
Q42025-12-3130.5%
Q12026-03-31-18.6%
Q22026-06-3023.2%
Arcutis Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5.6635.5%
20232023-12-31USD -3.78-33.2%
20242024-12-31USD -1.16-69.4%
20252025-12-31USD -0.13-89.0%
Arcutis Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30142.9%
Q42025-12-31133.0%
Q12026-03-31-167.2%
Q22026-06-30226.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$129.86M

+59.3%

Gross Profit

$118.92M

+60.7%

Gross Margin

91.58%

N/A

Market Cap

$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.98M

N/A

Employees

354

N/A

Net Income

$15.01M

+194.5%

EBITDA

$17.15M

+243.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$238.55M

+24.8%

Total Debt

$114.14M

+3.6%

Accounts Receivable

$155.16M

+45.4%

Inventory

$38.88M

+138.2%

Long Term Debt

$107.19M

-1.8%

Short Term Debt

$6.95M

+595.0%

Return on Assets

5.84%

N/A

Return on Invested Capital

10.44%

N/A

Free Cash Flow

$14.72M

+5883.7%

Operating Cash Flow

$14.88M

+4492.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IRONDisc Medicine, Inc.
$77.92+0.62%
TARSTarsus Pharmaceuticals, Inc.
$67.01+3.42%
ZLABZai Lab Limited
$23.22-0.43%
LEGNLegend Biotech Corporation
$20.61-0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.01-0.00%
ACHRArcher Aviation
$6.25+0.12%
NVDANvidia
$218.72-0.02%
INTCIntel
$98.69-0.03%

Questions About ARQT

What is the current price of Arcutis Biotherapeutics?

Arcutis Biotherapeutics is trading at $25.70 per share.

What is the 52-week range for Arcutis Biotherapeutics?

Over the past 52 weeks, Arcutis Biotherapeutics has traded between $14.03 and $31.77.

How much debt does Arcutis Biotherapeutics have?

As of the most recent reporting period, Arcutis Biotherapeutics reported total debt of $114.14M.

How much cash does Arcutis Biotherapeutics have on hand?

Arcutis Biotherapeutics reported $34.43M in cash and cash equivalents in its most recent financial results.

What is Arcutis Biotherapeutics’s dividend yield?

Arcutis Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services